Explore Our Publications
Entrada’s commitment to publications & transparency
Entrada is committed to publishing the results of our sponsored research in a transparent, scientifically accurate, and timely manner. Entrada will apply high ethical standards to our publications and presentations and will adhere to recognized industry guidance such as International Committee of Medical Journal Editors (ICMJE) Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals and International Society for Medical Publication Professionals (ISMPP) Good Publication Practice for Communicating Company Sponsored Medical Research.
Past Presentations
-
Endosomal Escape Vehicle (EEV™) - Oligonucleotides Conjugates Produce Exon Skipping and Dystrophin Production in Preclinical Models of Duchenne Muscular Dystrophy
- By: Mahasweta Girgenrath, PhD, Vice President Neuromuscular, Entrada Therapeutics
- At: 28th International Annual Congress of the World Muscle Society
- On: October 4, 2023
DownloadOctober 4, 2023 -
The Endosomal Escape Vehicle Platform Enhances the Delivery of Oligonucleotides to Skeletal and Cardiac Muscle
- By: Leo Ziqing Qian, PhD, Co-Founder & Vice President, Discovery Research, Entrada Therapeutics
- At: 2023 Sino-American Pharmaceutical Professionals Association (SAPA) Conference
- On: September 29, 2023
DownloadSeptember 29, 2023 -
Endosomal Escape Vehicle (EEV) - Oligonucleotide Conjugates Produce Exon Skipping and Dystrophin Production in Preclinical Models of Duchenne Muscular Dystrophy
- By: Aji Nair, PhD, Head of Scientific Communications, Entrada Therapeutics
- At: 2023 Neuromuscular Study Group Annual Scientific Meeting
- On: September 22, 2023
DownloadSeptember 22, 2023 -
Exon Skipping and Dystrophin Production with ENTR-601-45, a Novel EEV-Conjugated, Exon 45 Skip Amenable PMO in Preclinical Models of DMD
- By: Amy Hicks, PhD, Principal Scientist, Entrada Therapeutics
- At: Ottawa NMD 2023 Conference
- On: September 7, 2023
DownloadSeptember 7, 2023 -
The Endosomal Escape Vehicle Platform Enhances the Delivery of Oligonucleotides to Skeletal and Cardiac Muscle
- By: Leo Ziqing Qian, PhD, Co-Founder & Vice President, Discovery Research, Entrada Therapeutics
- At: RNA Leaders USA Congress
- On: September 6, 2023
DownloadSeptember 6, 2023 -
Endosomal Escape Vehicle (EEV™) Platform for Delivery of Oligonucleotides in Duchenne Muscular Dystrophy
- By: Nerissa Kreher, MD, Chief Medical Officer, Entrada Therapeutics
- At: Parent Project Muscular Dystrophy (PPMD) 2023 Annual Conference
- On: June 30, 2023
DownloadJune 30, 2023